Recently announced, medical device major
Boston Scientific Corporation
) began patient enrollment for its INTREPID trial in the U.S.
with the first implantation of its Vercise DBS System.
The INTREPID trial will analyze the clinical efficacy of its
Vercise DBS System for the treatment of Parkinson's disease. This
forthcoming clinical study conducted by Boston Scientific is a
multi-center, double-blind, randomized and control study to
assess the motor functions in affected patients.
The Vercise DBS System won the European CE Mark approval in the
third quarter of 2012. Boston Scientific also gained the
Australia Therapeutic Goods Administration (TGA) clearance for
the system. The company had earlier revealed plans to initiate a
clinical trial for the treatment of Parkinson's disease in the
U.S. in 2013.
According to findings from World Health Organization (WHO) and
Parkinson's Disease Foundation, Parkinson's disease is a
progressive neurodegenerative disorder that plagues over a
million individuals in the U.S. and about 7-10 million
individuals across the globe.
The emerging DBS therapy is a part of Boston Scientific's
neuromodulation business. Last month, Boston Scientific gained
the CE Mark approval in Europe for its GUIDE DBS System. Given
the untapped market opportunity, commercialization of DBS systems
should accelerate growth for the neuromodulation franchise.
BOSTON SCIENTIF (BSX): Free Stock Analysis
HAEMONETICS CP (HAE): Free Stock Analysis
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis
To read this article on Zacks.com click here.
As per the company's estimates, the global DBS market could
exceed $700 million by 2017 based on 10% CAGR. The
commercialization of innovative offerings to expand portfolio
should bolster revenues to achieve Boston Scientific's target of
$50 million in revenues from DBS therapy by 2017.
Currently, the stock carries a Zacks Rank #3 (Hold). The
company's peers such as
St. Jude Medical
) are also major players in the DBS market. While we have a
neutral stance on these med-tech majors,
), carrying a Zacks Rank #1 (Strong Buy) is worth